Abstract
Background
Atopic eczema (atopic dermatitis) is an itchy inflammatory skin condition that commonly requires topical therapy to control symptoms and flares[1]. Topical corticosteroids are widely used as first-line therapy for inflammatory eczema flares, but concerns about adverse effects can reduce adherence and worsen disease control[1].
Methods
This review synthesizes human clinical evidence drawn from randomized controlled trials and evidence syntheses that explicitly report efficacy and/or safety outcomes for topical therapies, including meta-analyses of topical corticosteroids and comparative network/meta-analytic assessments across multiple topical classes[2, 3]. A staged selection approach emphasizing studies meeting prespecified criteria and reporting clinical outcomes was aligned with how included systematic reviews describe identifying “trials meeting criteria” and summarizing comparative trial characteristics[4].
Results
Across evidence syntheses, moderate-potency topical corticosteroids, tacrolimus, and pimecrolimus were frequently among the most effective options for maintaining disease control, while pimecrolimus and tacrolimus also ranked highly for gaining control in comparative analyses[3]. Topical calcineurin inhibitors were associated with more local burning/pruritus than topical corticosteroids, but showed low rates of skin thinning and reassuring cancer risk estimates in large evidence syntheses[1, 5, 6]. Topical JAK inhibitors demonstrated rapid itch improvement and clinically meaningful disease improvements versus vehicle in controlled trials, with infrequent clinically significant application-site reactions in ruxolitinib studies and no serious adverse events reported in key delgocitinib trial periods[7, 8].
Conclusions
Current evidence supports a stepped approach built on emollients as foundational therapy, with topical corticosteroids as first-line anti-inflammatory treatment for flares and nonsteroidal options (calcineurin inhibitors, newer targeted topicals) used to reduce cumulative steroid exposure or address sensitive sites and patient preferences[1, 9, 10].
Introduction
Atopic eczema (atopic dermatitis) is defined clinically as an itchy inflammatory skin condition, and itch relief is therefore a core therapeutic target alongside suppression of visible inflammation[1]. Core topical anti-inflammatory approaches have historically relied on topical corticosteroids and topical calcineurin inhibitors, which are described as the mainstay of controlling skin inflammation in atopic dermatitis[8].
The rationale for comparing “eczema creams” is grounded in clinically meaningful trade-offs between speed of symptom relief, maintenance of control, and class-specific adverse-effect concerns that influence long-term adherence and escalation decisions[1, 4]. For example, topical corticosteroids are associated with a known potential for cutaneous atrophy-related adverse effects (e.g., telangiectasia, striae, purpura), and evidence syntheses also highlight potential systemic risks with prolonged or intensive use via increased percutaneous absorption in the context of barrier disruption[4].
In parallel, barrier-directed therapy is emphasized because moisturizers reduce transepidermal water loss and maintain hydration, supporting the conceptual link between barrier function and clinical control in atopic dermatitis care[11]. Emollients are repeatedly described as the cornerstone of basic therapy and first-line management in consensus recommendations and guidelines, reinforcing that “eczema creams” are not only anti-inflammatory drugs but also barrier-supportive interventions used chronically[9, 12].
Finally, comparative evidence and trial programs for newer nonsteroidal agents have been motivated by the need for topical treatments that are effective without the limitations of established therapies, as articulated in trial rationales calling for novel topical agents not burdened by safety/tolerability limitations[7].
Methods
This narrative scientific review was constructed from the provided evidence extracts, which include randomized controlled trials reporting validated clinical endpoints (e.g., EASI or modified EASI, Investigator’s Global Assessment outcomes, and itch numerical rating scales) and systematic evidence syntheses/meta-analyses that compare topical classes or summarize adverse events across topical therapies[2, 7, 8, 13]. Comparative inference was anchored where explicit comparative frameworks were available, including network meta-analytic statements about relative benefit for gaining and maintaining disease control and meta-analytic comparisons of adverse outcomes such as skin thinning[1, 3].
Evidence selection and synthesis were conducted in a staged manner emphasizing studies that “meet criteria” and report human clinical outcomes, consistent with how included systematic reviews describe screening to eligible trials and then characterizing included trial populations and comparators (e.g., pediatric trials of TCIs vs TCS and the presence/absence of vehicle controls)[4]. Because the review is constrained to the supplied text extracts, mechanistic discussion is limited to pathways explicitly described in those extracts (e.g., calcineurin pathway inhibition for TCIs and JAK inhibition for delgocitinib/ruxolitinib), and efficacy reporting emphasizes endpoints and time points explicitly presented (e.g., week 4 EASI change for ruxolitinib and delgocitinib, day-level itch changes, and meta-analytic response proportions for topical corticosteroids)[2, 7, 8, 14].
Topical corticosteroids
Topical corticosteroids are positioned in evidence summaries as first-line therapy for treating inflammatory eczema flares, and they have been FDA-approved for a variety of indications for decades, with a multifaceted mechanism described as having broad-spectrum impact on immune and skin barrier function[1, 4]. The clinical problem that motivates optimized use of topical corticosteroids is not only disease severity but also patient and clinician concern regarding adverse effects, which can contribute to poor adherence and worsen outcomes[1].
Efficacy evidence in the supplied dataset includes a meta-analysis in children reporting that 65% responded to topical corticosteroids compared with 32% responding to vehicle or moisturizer, supporting that topical corticosteroids provide clinically meaningful anti-inflammatory benefit beyond basic skin care in controlled settings[2]. Comparative effectiveness synthesis further indicates that moderate-potency corticosteroids are among the most effective options for maintaining atopic dermatitis control in network meta-analytic comparisons, which aligns with their longstanding role as a maintenance-capable anti-inflammatory strategy when used appropriately[3].
Safety concerns for topical corticosteroids in evidence summaries include skin thinning and potential effects on growth and development, which have contributed to ongoing patient worry and prioritization of long-term safety research[1, 15]. Reassuringly, a systematic evidence synthesis found no evidence that topical corticosteroids cause harm when used intermittently “as required” for flares or as “weekend therapy” to prevent flares, framing intermittent regimens as a key risk-mitigation approach[1].
When skin thinning is assessed comparatively, meta-analysis data showed a higher relative risk of skin thinning with topical corticosteroids than with topical calcineurin inhibitors, but the absolute event rate was low (0.4% with topical corticosteroids versus 0% with TCIs in the pooled dataset)[1]. Longer-duration randomized evidence was also reassuring for intermittent regimens, with a five-year randomized trial reporting only one episode of skin atrophy in the topical corticosteroid arm and supporting “little to no difference in skin thinning” when used intermittently to treat flares[15].
Potential systemic safety signals are addressed in evidence syntheses by distinguishing clinical from biochemical findings, with one review noting no clinical symptoms/signs of adrenal suppression and describing biochemical cortisol effects as transient with normalization after discontinuation[1]. Longer-term randomized evidence similarly reported no cases of clinical adrenal insufficiency in patients using mild/moderate potency topical corticosteroids, while observational case-control signals for type 2 diabetes and lymphoma were described as “very uncertain,” underscoring both the importance and limits of current long-term safety data[15].
In clinical placement, topical corticosteroids remain first-line for acute inflammatory flares, with evidence syntheses explicitly supporting intermittent “as required” use and proactive weekend therapy as practical strategies to maintain control while addressing safety concerns and adherence barriers[1].
Topical calcineurin inhibitors
Topical calcineurin inhibitors (tacrolimus and pimecrolimus) act by inhibiting T-cell activation through the calcineurin pathway, thereby inhibiting inflammatory cytokine release and interrupting downstream immune signaling relevant to atopic dermatitis inflammation[14]. In broader topical-therapy syntheses, TCIs are described as potentially useful steroid-sparing agents and as first-line topical anti-inflammatory treatment on the face and in skin folds, reflecting their value for sensitive sites where topical steroid adverse effects are particularly concerning[4].
In comparative efficacy evidence, a meta-analysis reported that calcineurin inhibitors were significantly more effective than various potency topical corticosteroids in physician global improvement, with a pooled relative effect favoring TCIs over TCS comparators in the analyzed trials[5]. Network meta-analytic comparative statements further suggest that pimecrolimus improves many outcomes for gaining control and that tacrolimus has intermediate benefit, supporting that TCIs are among the more effective nonsteroidal topical anti-inflammatory options in comparative frameworks[3].
The most consistently reported safety limitation is local tolerability, with meta-analytic evidence showing higher incidence of skin burning and pruritus with TCI treatment (including higher risk versus topical corticosteroids) and reviews explicitly stating that pimecrolimus and tacrolimus cause significantly more skin burning than topical corticosteroids[5, 14]. Long-term safety summaries report that burning and pruritus are the most common application-site events and that their prevalence decreases over time, with no increase in viral infections or other adverse events over time in the provided summary[16].
A clinically important differentiator is that tacrolimus ointment did not cause skin atrophy compared with hydrocortisone in a randomized comparison, supporting its role as a steroid-sparing choice in areas where atrophy risk is a key concern[17]. Consistent with this, pooled RCT comparisons described skin thinning as uncommon overall and observed no skin thinning events in the TCI arms in the cited pooled dataset[1].
Regarding the malignancy concern historically associated with TCIs, a systematic evidence synthesis reported that the absolute risk of any cancer with topical calcineurin inhibitor exposure was not different from controls and not different from the general US population, with an odds ratio close to 1 and moderate-certainty evidence, which provides context for clinical counseling in the setting of boxed-warning legacy concerns[6]. Pediatric trial synthesis similarly reported that cutaneous and systemic adverse events were similar in TCI and vehicle groups with no reports of lymphoma, supporting a reassuring safety signal in the summarized pediatric evidence base[4].
In clinical placement, topical corticosteroids remain first-line for acute inflammatory flares, with evidence syntheses explicitly supporting intermittent “as required” use and proactive weekend therapy as practical strategies to maintain control while addressing safety concerns and adherence barriers[1].
Topical JAK inhibitors
Topical JAK inhibitors are represented in the provided extracts by delgocitinib and ruxolitinib, with mechanistic descriptions emphasizing inhibition of Janus kinase signaling relevant to atopic dermatitis cytokine pathways[7, 8]. Delgocitinib is described as having inhibitory effects on JAK1, JAK2, JAK3, and tyrosine kinase 2, while ruxolitinib is described as a selective inhibitor of JAK1 and JAK2 that suppresses cytokine signaling involved in atopic dermatitis pathogenesis[7, 8].
Efficacy outcomes in randomized evidence show substantial improvements versus vehicle across validated measures. In an adult delgocitinib study, the least-squares mean percent change from baseline in modified EASI at week 4 was significantly greater with delgocitinib than with vehicle, demonstrating early anti-inflammatory benefit in controlled comparison[8]. A pediatric delgocitinib study similarly reported a significantly greater week 4 modified EASI improvement with delgocitinib than vehicle, supporting efficacy in younger populations in the extracted evidence[18].
Ruxolitinib trials similarly demonstrate clinically meaningful disease improvement and rapid symptom change. In a phase 2 program, all ruxolitinib regimens demonstrated therapeutic benefit at week 4, with 1.5% twice daily providing the greatest EASI and IGA responses versus vehicle in the reported comparison[7]. Rapid reductions in itch numerical rating scale score occurred within approximately 36 hours and were sustained through 12 weeks, positioning topical JAK inhibition as a notably rapid antipruritic option in the available trial evidence[7].
Phase 3 evidence further supports clinical response versus vehicle with ruxolitinib, with significantly more patients achieving IGA treatment success at week 8 for both 0.75% and 1.5% ruxolitinib cream compared with vehicle, and early itch NRS4 responses detectable by day 2 in the reported analysis[13]. In a pediatric/adolescent analysis, substantially more patients using 1.5% ruxolitinib cream achieved IGA treatment success, EASI-75, and itch NRS4 at week 8 compared with vehicle, and itch score reductions were significantly greater versus vehicle from day 2, supporting both efficacy and speed of itch relief in the extracted youth subgroup data[19].
Safety findings across the extracted topical JAK inhibitor trials are largely favorable in the reported endpoints. In delgocitinib randomized trial periods, no serious or severe adverse events and no adverse events leading to discontinuation were reported, and discontinuations due to adverse events occurred in only one patient in the cited report[8]. Longer-term delgocitinib safety summaries reported no skin atrophy or telangiectasia at application sites and infrequent, mild application-site irritation symptoms, supporting a low local atrophy/irritation signal in the cited extract[20].
In ruxolitinib studies, ruxolitinib was not associated with clinically significant application-site reactions, and application-site reactions were infrequent (<1%) and lower with ruxolitinib than vehicle in the reported phase 3 extract[7, 13]. Serious treatment-emergent adverse events were uncommon and none were considered related to ruxolitinib cream in the cited trial report, and the most common treatment-related adverse event (application-site burning sensation) was observed primarily with vehicle rather than ruxolitinib in the reported dataset, which supports favorable tolerability interpretation for ruxolitinib in the extracted evidence[13].
In terms of therapeutic positioning, topical corticosteroids and calcineurin inhibitors are described as mainstays but with safety concerns (e.g., skin atrophy and telangiectasia for topical corticosteroids and irritation symptoms for tacrolimus), and trial rationales explicitly state a need for novel topical agents not burdened by those limitations[7, 8]. Ruxolitinib is described as the first FDA-approved topical JAK inhibitor and is framed as a novel topical therapeutic option for atopic dermatitis, consistent with a role as a nonsteroidal anti-inflammatory alternative when topical selection is constrained by site, tolerability, or patient preferences[21].
Topical PDE4 inhibitors
Within the provided evidence extracts, this class is represented by clinical studies and comparative syntheses involving crisaborole, which is evaluated against vehicle in controlled designs and is also positioned in comparative summaries as having intermediate benefit with increased skin stinging and burning[3, 22]. Mechanistic detail for this class is not presented in the provided extracts, so this section focuses on clinical outcomes and tolerability as reported[22].
In an intrapatient randomized vehicle-controlled study, the primary endpoint (change from baseline in lesional total sign score at day 15) improved more with crisaborole-treated lesions than with vehicle-treated lesions, supporting efficacy against lesional signs/symptoms in a controlled comparison[22]. The same study reported early improvement in lesional signs/symptoms with pruritus improvement observed as early as 24 hours after first application and continued improvement through day 15, suggesting a relatively rapid antipruritic effect within the reported study framework[22].
Safety findings in crisaborole trials were generally reassuring in the extracted text. No serious adverse events were reported in the cited study, despite treatment-emergent adverse events being reported in a substantial proportion of participants during the double-blind and open-label periods, indicating that reported events were largely non-serious in that dataset[22]. During the double-blind period, crisaborole-related treatment-area adverse events were reported in a minority of patients and were described as mild application-site pain (primarily burning) or pruritus, consistent with the comparative synthesis statement that crisaborole increases skin stinging and burning despite intermediate benefit[3, 22].
In a phase 3 program summary, treatment-related adverse events were described as infrequent and mild-to-moderate in severity, and no treatment-related serious adverse events were reported, supporting a favorable serious-event profile in the extracted program-level statements[23]. In treatment sequencing discussions within the extracted dataset, the need for novel topical therapies that may improve the risk–benefit profile of current therapies is explicitly stated, which provides a rationale for considering nonsteroidal alternatives such as crisaborole when topical corticosteroid or calcineurin inhibitor limitations dominate decision-making[23].
Emollients and moisturizers
Emollients and moisturizers function primarily by limiting water loss and restoring the lipid composition of the stratum corneum, improving barrier function and xerosis and thereby reducing itching/pruritus and risks of infection in atopic dermatitis contexts described in the extracts[12]. Mechanistically, moisturizers are also described as enhancing eczema clearance by reducing transepidermal water loss and maintaining hydration, linking barrier support to clinical improvement in atopic dermatitis care[11].
Across guidelines and consensus statements quoted in the extracts, basic therapy with emollients remains the cornerstone of atopic dermatitis treatment, and emollients are considered first-line agents in management and are highly recommended by international consensus reports and guidelines[9, 12]. The concept of “emollients plus” is also presented, with formulations combining vehicle-type substances with additional active cosmetic ingredients described as having potential to exceed the effects of ordinary emollients and skin care routines in basic therapy, indicating an evolving formulation landscape within barrier-focused care[9].
Clinical efficacy signals
Clinical efficacy signals in the provided emollient trials include improvements in patient-reported and clinician-assessed outcomes. In a 12-week emollient-plus trial, a significant improvement in mean RECAP sum score with a rapid onset (54% reduction in the first 4 weeks) was reported, and peak pruritus was significantly reduced by 53% after 4 weeks with a majority of participants reaching a minimal clinically important difference on an NRS-11 scale[9]. In that same trial extract, mean vIGA-AD scores decreased by 63% over 12 weeks, supporting clinician-assessed improvement aligned with patient-reported symptom improvement in the reported dataset[9].
Emollients may also reduce reliance on more potent anti-inflammatory drugs in some settings. In an infant study summarized in the extracts, moderate- and high-potency topical corticosteroid use over 6 weeks decreased in the emollient group versus control, with a statistically significant reduction in high-potency corticosteroid consumption, supporting a corticosteroid-sparing signal in that controlled context[12].
Tolerability across the provided emollient studies was generally favorable. In the 12-week emollient-plus trial, high tolerability was reported with only one subject having treatment-related adverse events, and patient-reported satisfaction and tolerability were high, suggesting strong acceptability for routine use in the reported trial setting[9]. In the infant emollient trial, adverse events possibly treatment-related were mostly mild-to-moderate, with only two severe events leading to discontinuation, and all adverse events spontaneously resolved without sequelae, supporting overall safety for adjunctive use in the cited pediatric context while acknowledging that intolerance can occur[12].
In therapeutic placement, emollients are repeatedly framed as first-line and foundational therapy, and evidence synthesis statements emphasize that moisturizers can reduce the need for corticosteroids and prolong clinical improvement after discontinuation of therapy by improving skin barrier function, supporting routine integration with anti-inflammatory regimens and maintenance strategies[11, 12].
Comparative efficacy and safety
Comparative syntheses in the provided dataset suggest that more than one topical class can be among the most effective choices, depending on whether the goal is induction (gaining control) or maintenance (preventing relapse). For gaining control, comparative statements report that pimecrolimus improved the most outcomes, while tacrolimus, moderate-potency corticosteroids, delgocitinib, and ruxolitinib had intermediate benefit, which indicates that both established anti-inflammatories and newer targeted options can yield meaningful short-term control in comparative frameworks[3]. For maintaining control, moderate-potency corticosteroids were among the most effective options, followed by tacrolimus and pimecrolimus, which supports proactive strategies that use either intermittent steroid regimens or steroid-sparing maintenance therapy[3].
Adverse-effect profiles differ in ways that often drive site- and patient-specific selection. Long-term or more than once-daily topical corticosteroid use is described as being associated with subclinical barrier disruption that can result in rebound flares after discontinuation, and barrier disruption may contribute to increased percutaneous absorption with the possibility of rare systemic adverse events such as adrenal suppression and poor growth, illustrating why limiting intensity and duration is often emphasized in clinical algorithms[4]. Conversely, TCIs show a distinctive tolerability signature (burning/pruritus) but are associated with very low skin thinning incidence in pooled RCT comparisons and no difference in overall cancer risk versus controls in a large evidence synthesis, supporting their use when steroid-related atrophy concerns dominate decision-making[1, 5, 6].
Newer targeted topical agents in the provided extracts demonstrate promising efficacy with generally favorable tolerability signals, but long-term comparative positioning remains dependent on continued accumulation of data. Ruxolitinib trials report rapid itch reductions within approximately 36 hours and infrequent clinically significant application-site reactions, while delgocitinib trial summaries report no serious adverse events in key randomized periods and no observed skin atrophy/telangiectasia at application sites, suggesting a class profile that may be attractive for patients prioritizing rapid antipruritic response and nonsteroidal mechanisms[7, 8, 13, 20].
The table below summarizes practical, evidence-anchored comparative considerations across major topical “cream” categories based on the supplied extracts.
Treatment algorithm
A practical stepped-care approach is supported by guideline and consensus statements in the extracts that position basic therapy with emollients as the cornerstone of atopic dermatitis treatment and as first-line management across severity levels[9, 12]. In this model, moisturizers are used continuously to improve barrier function and can reduce the need for corticosteroids and prolong clinical improvement after discontinuation of therapy, supporting their role as the “base layer” of eczema cream use even when pharmacologic anti-inflammatories are added[11].
For active inflammatory flares, topical corticosteroids remain first-line therapy in evidence summaries, but expert algorithm statements emphasize limiting topical corticosteroids to intermittent short-term use, reflecting risk management for cutaneous and potential systemic effects described in safety syntheses[1, 10]. Evidence syntheses supporting intermittent “as required” and weekend therapy regimens provide an evidence-based structure for proactive maintenance while addressing common safety worries and adherence barriers reported in the extracts[1].
After achieving treatment goals, evidence-based algorithm statements recommend continuing noncorticosteroid topical maintenance therapy to prevent flares and reduce the need for topical corticosteroids, which conceptually aligns with comparative maintenance rankings where moderate-potency corticosteroids, tacrolimus, and pimecrolimus are among effective maintenance choices in the cited comparative synthesis[3, 10]. In practice, TCIs are specifically described as steroid-sparing agents and as first-line topical anti-inflammatory treatment on the face and in skin folds, supporting their preferential use in sensitive sites and in patients at higher risk of steroid adverse effects[4].
For patients with inadequate control, intolerance, or preference constraints, trial rationales and approvals support consideration of newer targeted topicals. The need for novel topical agents not burdened by limitations of mainstay therapies is stated in the ruxolitinib development rationale, and ruxolitinib is described as the first FDA-approved topical JAK inhibitor, which supports its placement as a modern nonsteroidal anti-inflammatory option in topical sequencing[7, 21]. This positioning also aligns with statements that most patients with atopic dermatitis can be effectively managed without systemic therapy and that some patients and clinicians may prefer topical over systemic treatment, even with larger body surface area involvement, which strengthens the relevance of optimized topical strategies[24].
Limitations
The evidence summarized here is constrained by the scope and detail of the provided extracts, which do not uniformly present mechanistic explanations for all topical classes (e.g., mechanistic detail for crisaborole is not included in the supplied text), limiting the depth of mechanistic comparison that can be made from the provided material[22]. Comparative interpretation is also affected by heterogeneity in comparators and trial design, as highlighted in a systematic review noting that topical corticosteroid studies in a pediatric comparative set were limited to low- to mid-potency products and that most lacked a vehicle control, which can complicate across-class benchmarking[4].
Long-term safety inference remains an ongoing challenge, despite reassuring findings for intermittent topical corticosteroid regimens, because patient worry about long-term adverse effects persists and long-term safety has been prioritized for future research in the extracted evidence base[1, 15]. Similarly, while long-term or intensive topical corticosteroid use is described as being associated with subclinical barrier disruption and potential systemic adverse events through increased percutaneous absorption, these risks are described as rare and difficult to quantify, indicating persistent uncertainty about risk magnitude in real-world use patterns not directly tested in long-duration controlled trials[4].
Finally, the need for novel topical agents “highly effective and not burdened with the limitations” of available treatments underscores that evidence gaps remain, particularly regarding head-to-head comparative effectiveness and durability of response across diverse patient populations and anatomical sites, even as newer topical agents show favorable short-term trial signals in the provided extracts[7].
Conclusions
Across the provided evidence, topical therapy for atopic dermatitis can be conceptualized as a combination of barrier restoration (emollients/moisturizers) and anti-inflammatory control (topical corticosteroids and nonsteroidal immunomodulators/targeted agents), with emollients described as cornerstone/first-line care and topical corticosteroids described as first-line for inflammatory flares[1, 9]. Intermittent topical corticosteroid regimens, including “as required” flare treatment and weekend therapy for prevention, are supported by evidence syntheses as not showing harm in the reviewed data, which provides a practical foundation for balancing efficacy and safety concerns that commonly influence adherence[1].
Topical calcineurin inhibitors offer effective steroid-sparing control with low atrophy risk but more frequent local burning/pruritus, and large evidence syntheses report no difference in overall cancer risk versus controls, supporting their continued use especially on the face and intertriginous sites where steroid adverse effects are a major concern[4–6]. Newer topical JAK inhibitors demonstrate rapid itch relief and robust improvement in disease severity measures in vehicle-controlled trials with infrequent clinically significant application-site reactions and low serious adverse-event signals in the cited trial extracts, supporting their role as modern nonsteroidal options within topical sequencing for appropriately selected patients[7, 8, 13].
Taken together, the evidence supports a stepped, patient-centered algorithm that begins with consistent emollient use, uses topical corticosteroids judiciously for flares, and layers steroid-sparing maintenance options (e.g., TCIs and other noncorticosteroid topicals) after treatment goals are achieved to prevent flares and reduce cumulative steroid exposure[9, 10].
